California First Leasing Corporation (CFNB)

Inozyme Pharma Income Statement

Financials in millions USD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Operating Revenue	4.17	1.28	2.07	0.95	0.8	1.45
Other Revenue	3.66	47.96	22.48	-16.92	47.95	3.29
Revenue	7.83	49.24	24.56	-15.97	48.75	4.74
Revenue Growth (YoY)	-86.11%	100.53%	-	-	929.65%	-72.05%
Cost of Revenue	-0.08	-0.08	-0.16	-0.22	-0.3	-0.58
Gross Profit	7.91	49.32	24.72	-15.75	49.05	5.32
Selling, General & Admin	2.69	2.73	2.79	3.03	4.27	5.61
Operating Expenses	2.69	2.73	2.79	3.03	4.27	5.61
Operating Income	5.23	46.59	21.93	-18.79	44.78	-0.29
EBT Excluding Unusual Items	5.23	46.59	21.93	-18.79	44.78	-0.29
Gain (Loss) on Sale of Assets	-	-	-	-	2.34	-
Pretax Income	5.23	46.59	21.93	-18.79	47.12	-0.29
Income Tax Expense	0.64	13.02	5.07	-6.13	10.89	2.07
Net Income	4.59	33.57	16.86	-12.66	36.23	-2.36
Net Income to Common	4.59	33.57	16.86	-12.66	36.23	-2.36
Net Income Growth	-88.22%	99.08%	-	-	-	-
Shares Outstanding (Basic)	9	9	10	10	10	10
Shares Outstanding (Diluted)	9	9	10	10	10	10
Shares Change (YoY)	-2.79%	-4.93%	-3.06%	-	-	-
EPS (Basic)	0.49	3.54	1.69	-1.23	3.52	-0.23
EPS (Diluted)	0.49	3.54	1.69	-1.23	3.52	-0.23
EPS Growth	-87.89%	109.41%	-	-	-	-
Dividend Per Share	-	0.400	-	0.560	0.540	0.520
Dividend Growth	-	-	-	3.70%	3.85%	4.00%
Gross Margin	101.02%	100.16%	100.65%	-	100.61%	112.29%
Operating Margin	66.72%	94.61%	89.31%	-	91.85%	-6.13%
Profit Margin	58.56%	68.17%	68.67%	-	74.31%	-49.91%
EBITDA	5.36	46.68	21.98	-18.71	44.89	0.2
EBITDA Margin	68.38%	94.80%	89.50%	-	92.07%	4.20%
D&A For EBITDA	0.13	0.1	0.05	0.07	0.11	0.49
EBIT	5.23	46.59	21.93	-18.79	44.78	-0.29
EBIT Margin	66.72%	94.61%	89.31%	-	91.85%	-6.13%
Effective Tax Rate	12.22%	27.94%	23.11%	-	23.11%	-
Revenue as Reported	2.46	2.46	5.07	3.75	9.78	-

Updated Feb 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.